Deal Overview
Axcelead Drug Discovery Partners (Axcelead DDP), a Japanese drug discovery company, has entered into a strategic research and collaboration agreement with Eli Lilly and Company (Lilly), a global pharmaceutical leader. Announced on September 5, 2024, the collaboration aims to leverage Axcelead DDP’s innovative drug discovery technologies to support multiple drug discovery programs for Lilly. This partnership highlights Axcelead DDP’s growing reputation in the industry and its ability to develop new drug candidates through cutting-edge research.
Axcelead’s capabilities and partnership focus:
Axcelead DDP is recognized for its strong drug discovery capabilities, which include the use of artificial intelligence (AI) and other novel technologies to accelerate the development of new drugs. With deep expertise and extensive experience in the field, Axcelead DDP is well-positioned to contribute to innovative breakthroughs in drug discovery. According to Kengo Okada, PhD, CEO of Axcelead DDP, the company is committed to enhancing Lilly’s drug pipeline by delivering high-quality drug candidates with the potential to transform healthcare and improve lives worldwide.
Financial Terms and Synergies:
Under the terms of the agreement, Axcelead DDP will receive an upfront payment from Lilly and is eligible for additional milestone payments as each drug discovery program progresses. The collaboration enables both companies to pool their resources and expertise to accelerate the development of new therapeutic candidates, positioning the partnership for long-term success in delivering life-changing medicines to patients globally.